Banque Pictet & Cie SA Sells 22,425 Shares of Moderna, Inc. (NASDAQ:MRNA)

Banque Pictet & Cie SA decreased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 0.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,132,974 shares of the company’s stock after selling 22,425 shares during the period. Moderna accounts for approximately 0.9% of Banque Pictet & Cie SA’s holdings, making the stock its 16th biggest holding. Banque Pictet & Cie SA owned about 0.81% of Moderna worth $130,269,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of MRNA. Intrinsic Value Partners LLC increased its holdings in shares of Moderna by 91.1% in the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock valued at $3,435,000 after purchasing an additional 24,505 shares in the last quarter. Banco Santander S.A. bought a new position in Moderna in the 3rd quarter valued at $3,550,000. John G Ullman & Associates Inc. increased its stake in shares of Moderna by 341.3% in the 3rd quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock valued at $3,318,000 after buying an additional 38,400 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Moderna by 11.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after buying an additional 167,596 shares during the period. Finally, abrdn plc raised its position in shares of Moderna by 28.1% during the fourth quarter. abrdn plc now owns 315,912 shares of the company’s stock worth $12,842,000 after acquiring an additional 69,360 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Up 4.6 %

MRNA opened at $31.92 on Friday. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 12 month low of $30.24 and a 12 month high of $170.47. The firm’s fifty day simple moving average is $39.31 and its 200 day simple moving average is $55.94.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 2,664 shares of company stock valued at $115,210 in the last 90 days. 15.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

MRNA has been the topic of several recent research reports. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a report on Monday, November 18th. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Evercore ISI dropped their price target on shares of Moderna from $60.00 to $50.00 and set an “in-line” rating for the company in a research note on Monday, January 27th. Barclays reduced their price objective on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Finally, Piper Sandler reiterated an “overweight” rating and set a $69.00 target price (down previously from $115.00) on shares of Moderna in a research report on Monday, November 18th. Four equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Moderna has an average rating of “Hold” and a consensus price target of $66.89.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.